bPiDI

Overview

bPiDI is a novel selective α6β2 nicotinic receptor antagonist. bPiDI inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Depression | Products > Disease Areas > Parkinson's Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > nAChR

Product Information

• Catalog No.: HY-152170
• CAS No.: 525596-64-9
• Molecular Formula: C22H34I2N2
• Molecular Weight: 580.33
• Purity: 99.65%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: 5 mg/mL (8.62 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source